CA2113279A1 - Utilisation de l'alpha-cetoglutarate - Google Patents

Utilisation de l'alpha-cetoglutarate

Info

Publication number: CA2113279A1
Authority: CA; Canada
Prior art keywords: alpha; ketoglutarate; glutamine; analogues; amino acid
Prior art date: 1992-05-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002113279A

Other languages

English (en)

Inventor

Erik Vinnars

Jan Wernerman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vinnars Erik AB

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-20

Filing date

1993-05-14

Publication date

1993-11-25

1993-05-14 Application filed by Individual filed Critical Individual

1993-11-25 Publication of CA2113279A1 publication Critical patent/CA2113279A1/fr

Status Abandoned legal-status Critical Current

Links

KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 title claims abstract description 58
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 47
229940024606 amino acid Drugs 0.000 claims abstract description 39
150000001413 amino acids Chemical class 0.000 claims abstract description 39
208000028399 Critical Illness Diseases 0.000 claims abstract description 28
210000002027 skeletal muscle Anatomy 0.000 claims abstract description 25
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 24
239000000203 mixture Substances 0.000 claims abstract description 24
238000001243 protein synthesis Methods 0.000 claims abstract description 17
230000014616 translation Effects 0.000 claims abstract description 17
229960001230 asparagine Drugs 0.000 claims abstract description 13
239000003814 drug Substances 0.000 claims abstract description 13
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims abstract description 12
230000037396 body weight Effects 0.000 claims abstract description 10
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 8
239000008103 glucose Substances 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 44
235000001014 amino acid Nutrition 0.000 description 32
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
239000000243 solution Substances 0.000 description 21
210000003205 muscle Anatomy 0.000 description 17
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 16
229910052757 nitrogen Inorganic materials 0.000 description 11
235000016709 nutrition Nutrition 0.000 description 11
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
229950007002 phosphocreatine Drugs 0.000 description 8
235000021476 total parenteral nutrition Nutrition 0.000 description 8
208000014674 injury Diseases 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 6
229930182816 L-glutamine Natural products 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
230000002980 postoperative effect Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
229960003624 creatine Drugs 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
208000034657 Convalescence Diseases 0.000 description 3
108010016626 Dipeptides Proteins 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
210000003445 biliary tract Anatomy 0.000 description 3
239000006046 creatine Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000035764 nutrition Effects 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
235000002374 tyrosine Nutrition 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
208000034486 Multi-organ failure Diseases 0.000 description 2
208000010718 Multiple Organ Failure Diseases 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
238000012084 abdominal surgery Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
238000002283 elective surgery Methods 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000005399 mechanical ventilation Methods 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
230000003387 muscular Effects 0.000 description 2
235000016236 parenteral nutrition Nutrition 0.000 description 2
210000003314 quadriceps muscle Anatomy 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000008733 trauma Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SLPUVFBNQHVEEU-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;2-oxopentanedioic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CCC(=O)C(O)=O SLPUVFBNQHVEEU-WCCKRBBISA-N 0.000 description 1
HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical compound OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 description 1
VUTGNDXEFRHDDC-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)-n-(2-oxooxolan-3-yl)acetamide;2-(trichloromethylsulfanyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1.CC1=CC=CC(C)=C1N(C(=O)CCl)C1C(=O)OCC1 VUTGNDXEFRHDDC-UHFFFAOYSA-N 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
241001254607 Leander Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000005693 branched-chain amino acids Chemical class 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
-1 glucose and the like Chemical class 0.000 description 1
150000002308 glutamine derivatives Chemical class 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940075858 ornithine alpha-ketoglutarate Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002113279A 1992-05-20 1993-05-14 Utilisation de l'alpha-cetoglutarate Abandoned CA2113279A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9201584A SE9201584D0 (sv)	1992-05-20	1992-05-20	Use of alpha-ketoglutarate
SE9201584-1		1992-05-20

Publications (1)

Publication Number	Publication Date
CA2113279A1 true CA2113279A1 (fr)	1993-11-25

Family

ID=20386290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002113279A Abandoned CA2113279A1 (fr)	1992-05-20	1993-05-14	Utilisation de l'alpha-cetoglutarate

Country Status (7)

Country	Link
EP (1)	EP0612245A1 (fr)
JP (1)	JPH06509362A (fr)
AU (1)	AU661399B2 (fr)
CA (1)	CA2113279A1 (fr)
NO (1)	NO306195B1 (fr)
SE (1)	SE9201584D0 (fr)
WO (1)	WO1993023027A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007053943A1 (fr) *	2005-11-08	2007-05-18	Multi Formulations Ltd.	Utilisation de compositions comprenant des cetoacides et des acides amines pour accroitre la masse et les performances musculaires

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9303691D0 (sv) *	1993-11-09	1993-11-09	Gramineer Ab	New beverage
SE9402027D0 (sv) *	1994-06-10	1994-06-10	Pharmacia Ab	Energy substrates
US20050085498A1 (en) *	1998-05-28	2005-04-21	Byrd Edward A.	Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US20020147237A1 (en) *	2001-01-31	2002-10-10	Lars Wiklund	Preservation of bodily protein
SK11252003A3 (sk) *	2001-02-14	2003-12-02	Matthias Rath	Kompozície biochemických zlúčenín zúčastňujúcich sa bioenergetického metabolizmu buniek a ich použitie
SE0301947D0 (sv) *	2003-07-01	2003-07-01	Gramineer Internat Ab	New method and uses
CN103491804A (zh) *	2011-04-18	2014-01-01	雀巢产品技术援助有限公司	具有α-HICA 和二十碳五烯酸的营养组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0250559A1 (fr) *	1985-12-18	1988-01-07	VEECH, Richard L.	Therapie de nutrition parenterale avec acides amines
SE8704217D0 (sv) *	1987-10-29	1987-10-29	Vinnars Erik Ab	Aminosyrakomposition for parenteral neringstillforsel

1992
- 1992-05-20 SE SE9201584A patent/SE9201584D0/xx unknown
1993
- 1993-05-14 EP EP93910529A patent/EP0612245A1/fr not_active Withdrawn
- 1993-05-14 AU AU40989/93A patent/AU661399B2/en not_active Ceased
- 1993-05-14 JP JP5520133A patent/JPH06509362A/ja active Pending
- 1993-05-14 CA CA002113279A patent/CA2113279A1/fr not_active Abandoned
- 1993-05-14 WO PCT/SE1993/000426 patent/WO1993023027A1/fr not_active Ceased
1994
- 1994-01-19 NO NO940190A patent/NO306195B1/no not_active IP Right Cessation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007053943A1 (fr) *	2005-11-08	2007-05-18	Multi Formulations Ltd.	Utilisation de compositions comprenant des cetoacides et des acides amines pour accroitre la masse et les performances musculaires

Also Published As

Publication number	Publication date
NO940190L (no)	1994-01-19
AU661399B2 (en)	1995-07-20
NO940190D0 (no)	1994-01-19
SE9201584D0 (sv)	1992-05-20
AU4098993A (en)	1993-12-13
JPH06509362A (ja)	1994-10-20
WO1993023027A1 (fr)	1993-11-25
NO306195B1 (no)	1999-10-04
EP0612245A1 (fr)	1994-08-31

Legal Events

Date	Code	Title	Description
2000-04-20	EEER	Examination request
2003-05-14	FZDE	Dead

Publication	Publication Date	Title
EP0318446B1 (fr)	1992-10-14	Composition d'acides amines comme support dans la nutrition parentérale
EP0347890B1 (fr)	1993-03-17	Compositions nutritives contenant des acides aminés
US5719119A (en)	1998-02-17	Parenteral nutrition therapy with amino acids
TWI429405B (zh)	2014-03-11	用於靜脈營養療法的小兒胺基酸溶液
US4780475A (en)	1988-10-25	Preparation for the prevention of catabolism
JPH0811728B2 (ja)	1996-02-07	栄養輸液用アミノ酸溶液、その調製法及び使用法
EP0238553B1 (fr)	1997-05-07	Traitement d'un dereglement catabolique
JPH0331211A (ja)	1991-02-12	腎不全のための栄養組成物
US5276018A (en)	1994-01-04	Composition comprising amino acids and methods for decreasing muscle breakdown
US5646187A (en)	1997-07-08	Use of alpha-ketoglutarate
CA2113279A1 (fr)	1993-11-25	Utilisation de l'alpha-cetoglutarate
JP2599593B2 (ja)	1997-04-09	腎不全用アミノ酸輸液
JPH0463049B2 (fr)	1992-10-08
US5310768A (en)	1994-05-10	Method for improving the glutamine content in skeletal muscle and composition therefore
JPH03204814A (ja)	1991-09-06	腎不全用経口アミノ酸製剤
CA1334575C (fr)	1995-02-28	Preparation liquide de substitution contenant de l'acide 3-hydroxybutyrique (acide beta-hydroxybutyrique) et ses sels
Meguid et al.	1984	Effect of elemental diet on albumin and urea synthesis: comparison with partially hydrolyzed protein diet
JPS61502822A (ja)	1986-12-04	全非経口栄養及び経腸栄養組成物
JPH03264525A (ja)	1991-11-25	アミノ酸輸液
WO1982003552A1 (fr)	1982-10-28	Solution amelioree pour nutrition par voie parenterale
JP3429327B2 (ja)	2003-07-22	癌用アミノ酸輸液剤
JPH09110686A (ja)	1997-04-28	マクロファージ一酸化窒素産生亢進剤
WO1995022967A1 (fr)	1995-08-31	Stimulateur de l'activite analgesique
EP0147682A1 (fr)	1985-07-10	Solution d'infusion d'aminoacides
JPS62135421A (ja)	1987-06-18	癌用アミノ酸輸液

CA2113279A1 - Utilisation de l'alpha-cetoglutarate - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=20386290

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (7)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents

Legal Events